Cargando…
Practical implementation of a q4–q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel
OBJECTIVES: This report, based on guidance from a panel of UK retina specialists, introduces a revised intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) pathway for the treatment of neovascular age-related macular degeneration (nAMD). The T&E pathway incorporates the updated IVT-AFL...
Autores principales: | Bailey, Clare, Cackett, Peter, Kotagiri, Ajay, Mahmood, Sajjad, Minos, Evangelos, Narendran, Nirodhini, Patwardhan, Ashish, Sim, Dawn A., Morgan-Warren, Peter, O’Neil, Carolyn, Straw, Katie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542445/ https://www.ncbi.nlm.nih.gov/pubmed/36207506 http://dx.doi.org/10.1038/s41433-022-02264-3 |
Ejemplares similares
-
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
por: Ross, Adam H., et al.
Publicado: (2020) -
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017) -
Panel discussion with the experts - Q&A interaction
por: Guichard, Romain, et al.
Publicado: (2022) -
Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018) -
Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan, Randhir, et al.
Publicado: (2014)